Georger Minot News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article NEW YORK and PERTH, Australia, March 17, 2021 /PRNewswire/  PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced the appointment of Michael Rosenblatt, MD, to its Board of Directors. Dr. Rosenblatt is a Senior Partner at Flagship Pioneering, a leading-edge innovation organization that conceives, creates and develops first-in-category life science companies, and the former Chief Medical Officer of Merck, one of the world s leading global biopharmaceutical companies. Dr. Rosenblatt brings over four decades of visionary leadership experience across biopharmaceutical companies and academic institutions, and as a practicing physician. In his current role at Flagship, he has helped launch several renowned biotechnology companies in the Flagship ecosystem, including providing counsel on clinical development strategies a

Tufts universityUnited statesWestern australiaOhana biosciencesMichael rosenblattSahm nasseriRoberth ebertGeorger minotVaccine acceleration committeeHarvard medical schoolRadius pharmaceuticalsColumbia universityHuman genome sciencesModerna therapeutic development committee of the boardDivision of health sciencesDean of tufts university school medicine